- Home
- PBH vs OGN Comparison
PBH vs OGN Comparison
Compare PBH & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBH
- OGN
- Stock Information
- Founded
- PBH 1996
- OGN 1923
- Country
- PBH United States
- OGN United States
- Employees
- PBH N/A
- OGN N/A
- Industry
- PBH Biotechnology: Pharmaceutical Preparations
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- PBH Health Care
- OGN Health Care
- Exchange
- PBH Nasdaq
- OGN Nasdaq
- Market Cap
- PBH 4.0B
- OGN 4.7B
- IPO Year
- PBH 2005
- OGN N/A
- Fundamental
- Price
- PBH $84.17
- OGN $14.89
- Analyst Decision
- PBH Strong Buy
- OGN Hold
- Analyst Count
- PBH 3
- OGN 3
- Target Price
- PBH $83.67
- OGN $21.33
- AVG Volume (30 Days)
- PBH 306.9K
- OGN 3.2M
- Earning Date
- PBH 11-07-2024
- OGN 10-31-2024
- Dividend Yield
- PBH N/A
- OGN 7.51%
- EPS Growth
- PBH N/A
- OGN 120.97
- EPS
- PBH 4.10
- OGN 5.04
- Revenue
- PBH $1,110,659,000.00
- OGN $6,409,000,000.00
- Revenue This Year
- PBH $1.57
- OGN $3.13
- Revenue Next Year
- PBH $2.54
- OGN $2.18
- P/E Ratio
- PBH $20.41
- OGN $2.95
- Revenue Growth
- PBH N/A
- OGN 4.21
- 52 Week Low
- PBH $56.61
- OGN $10.84
- 52 Week High
- PBH $84.21
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- PBH 80.59
- OGN 29.13
- Support Level
- PBH $80.35
- OGN $14.39
- Resistance Level
- PBH $83.83
- OGN $15.85
- Average True Range (ATR)
- PBH 2.00
- OGN 0.56
- MACD
- PBH 0.34
- OGN -0.08
- Stochastic Oscillator
- PBH 99.13
- OGN 13.76
About PBH Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.